Postoperative PainNCT07810413
Anrikefon Injection for Postoperative Analgesia in Thoracoscopic Lung Surgery: A Randomized, Double-Blind, Active-Controlled, Parallel-Group, Single-Center Clinical Study
A study testing Anrikefon Injection and Sufentanil Citrate Injection in people with Postoperative Pain, run by The First People's Hospital of Lianyungang.
Trial summary
This is a randomized, double-blind, active-controlled clinical study evaluating the efficacy and safety of Anrikefon (HSK21542) Injection for patient-controlled analgesia (PCA) in patients undergoing thoracoscopic lung surgery. Subjects aged 18-85 years with a postoperative resting NRS score ≥ 4 will be enrolled. Read more about this study
- Who is it for?
- Ages 18 to 85 years
- Conditions the study is for
- Postoperative Pain
- What is being tested?
- Anrikefon Injection and Sufentanil Citrate Injection
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 88 participants
- Where
- No sites listed yet
- Study dates
- 30 Sep 2026to 30 May 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 85 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age 18 to 85 years (inclusive), either sex.
- Body mass index (BMI) 18.0 to 30.0 kg/m² (inclusive).
- American Society of Anesthesiologists (ASA) physical status Class I to III preoperatively.
- Undergoing elective thoracoscopic lung surgery under general anesthesia (complete video-assisted thoracoscopic surgery, without conversion to thoracotomy), with successful recovery from anesthesia within 1 hour postoperatively, fully awake, able to accurately complete NRS scoring with an NRS score ≥ 4, and willing to accept the analgesic regimen defined in the study protocol.
- Able to understand the purpose, procedures, and scale scoring methods of the study, capable of operating the PCA device, and able to communicate effectively with investigators.
- Voluntarily participating and providing written informed consent.
Who cannot join
- Known or suspected allergy or contraindication to any of the study drugs.
- History of opioid abuse, drug or alcohol dependence, or current preoperative use of opioids.
- Use of analgesic medications (acetaminophen, NSAIDs, opioids, tramadol, etc.) within 24 hours preoperatively.
- Uncontrolled severe cardiovascular disease (second-degree or higher atrioventricular block, resting heart rate < 50 bpm, uncontrolled hypertension, myocardial infarction or unstable angina within the past 6 months), hepatic insufficiency (ALT/AST > 2× upper limit of normal), renal insufficiency (eGFR < 30 mL/min/1.73m² or maintenance dialysis), neuropsychiatric dysfunction, or inability to cooperate with pain assessment.
- History of chronic pain.
- Severe respiratory or circulatory failure during anesthesia/surgery (including intraoperative conversion to thoracotomy, operative time > 6 hours, or intraoperative hemorrhage > 1000 mL).
Show all 9Show fewer
- Pregnancy or lactation, or positive urine pregnancy test in women of childbearing potential.
- Participation in another drug/device clinical trial within 30 days before randomization.
- Any other condition that the investigator deems unsuitable for participation.
About this study
This is a randomized, double-blind, active-controlled clinical study evaluating the efficacy and safety of Anrikefon (HSK21542) Injection for patient-controlled analgesia (PCA) in patients undergoing thoracoscopic lung surgery. Subjects aged 18-85 years with a postoperative resting NRS score ≥ 4 will be enrolled. Eligible participants will be randomized 1:1 to receive either Anrikefon (HSK21542) or sufentanil via PCA pump for 24 hours post-surgery. The primary endpoint is the 24-hour summed pain intensity difference (SPID₂₄). A total of 88 subjects are planned for enrollment. The study has received ethics committee approval.
- Conditions
- Postoperative Pain
- Being tested
- Anrikefon Injection, Sufentanil Citrate Injection
- Keywords
- Thoracic Surgery, Anrikefon, Sufentanil
- Medical subject headings
- Pain, Postoperative
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Anrikefon InjectionDrug
Active ingredient: Anrikefon. Specification: 1 mL: 0.1 mg. Dosage: diluted to working solution of 10 μg/mL in 100 mL; loading dose 1.0 μg/kg; PCA bolus 2 mL per demand; lockout interval 15 min.
Sufentanil Citrate InjectionDrug
Specification: 1 mL: 50 μg. Dosage: 2 μg/kg diluted to 100 mL solution; loading dose 0.1 μg/kg; PCA bolus 2 mL per demand; lockout interval 15 min.
| Study group | Role | What they receive |
|---|---|---|
| Anrikefon (HSK21542) Group | Experimental | Not described Receives: Drug: Anrikefon Injection |
| Sufentanil Group | Active comparator | Not described Receives: Drug: Sufentanil Citrate Injection |
What is being measured
The primary outcome is the main question the study is designed to answer.
Sum of Pain Intensity Difference over 24 Hours (SPID₂₄)
Measured: 0 to 24 hours after first dose
Secondary outcomes (6)
Number and Dose of Rescue Medication
Measured: 0 to 24 hours after first dose
Incidence of Postoperative Nausea and Vomiting (PONV) at 24 Hours
Measured: 0 to 24 hours after first dose
PCA Pump Demand (Total, Effective, and Delivered Dose)
Measured: 0 to 24 hours after first dose
Time to First Rescue Medication
Measured: 0 to 24 hours after first dose
Proportion of Subjects Requiring Rescue Medication
Measured: 0 to 24 hours after first dose
Treatment Failure Rate Due to Inadequate Analgesia
Measured: 0 to 24 hours after first dose
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Sep 2026
- Study start30 Sep 2026 (estimated)
- Primary completion31 Dec 2026 (estimated)
- Study completion30 May 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Postoperative PainStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 88 participants (estimated)
Sponsor and investigators
- Lead sponsor
- The First People's Hospital of Lianyungang
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07810413
- Sponsor's protocol ID
- KY-20250709002-02
- Status last verified
- Aug 2026
- First submitted
- 3 Sep 2026
- Last updated
- 9 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 9 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Anrikefon Injection for Postoperative Analgesia in Thoracoscopic Lung Surgery: A Randomized, Double-Blind, Active-Controlled, Parallel-Group, Single-Center Clinical Study
- ClinicalTrials.gov ID
- NCT07810413
- Acronym / sponsor ID
- KY-20250709002-02
- Conditions
- Postoperative Pain
- Keywords
- Thoracic Surgery, Anrikefon, Sufentanil
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 88 participants (estimated)
- Lead sponsor
- The First People's Hospital of LianyungangUniversity, hospital or other
- Study start
- 30 Sep 2026 (estimated)
- Primary completion
- 31 Dec 2026 (estimated)
- Study completion
- 30 May 2027 (estimated)
- First posted
- 9 Sep 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a randomized, double-blind, active-controlled clinical study evaluating the efficacy and safety of Anrikefon (HSK21542) Injection for patient-controlled analgesia (PCA) in patients undergoing thoracoscopic lung surgery. Subjects aged 18-85 years with a postoperative resting NRS score ≥ 4 will be enrolled. Eligible participants will be randomized 1:1 to receive either Anrikefon (HSK21542) or sufentanil via PCA pump for 24 hours post-surgery. The primary endpoint is the 24-hour summed pain intensity difference (SPID₂₄). A total of 88 subjects are planned for enrollment. The study has received ethics committee approval.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Anrikefon (HSK21542) Group | Experimental | Drug: Anrikefon Injection |
| Sufentanil Group | Active comparator | Drug: Sufentanil Citrate Injection |
Who may qualify
- Ages
- 18 to 85 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Age 18 to 85 years (inclusive), either sex.
- Body mass index (BMI) 18.0 to 30.0 kg/m² (inclusive).
- American Society of Anesthesiologists (ASA) physical status Class I to III preoperatively.
- Undergoing elective thoracoscopic lung surgery under general anesthesia (complete video-assisted thoracoscopic surgery, without conversion to thoracotomy), with successful recovery from anesthesia within 1 hour postoperatively, fully awake, able to accurately complete NRS scoring with an NRS score ≥ 4, and willing to accept the analgesic regimen defined in the study protocol.
- Able to understand the purpose, procedures, and scale scoring methods of the study, capable of operating the PCA device, and able to communicate effectively with investigators.
Key exclusion criteria (9 listed)
- Known or suspected allergy or contraindication to any of the study drugs.
- History of opioid abuse, drug or alcohol dependence, or current preoperative use of opioids.
- Use of analgesic medications (acetaminophen, NSAIDs, opioids, tramadol, etc.) within 24 hours preoperatively.
- Uncontrolled severe cardiovascular disease (second-degree or higher atrioventricular block, resting heart rate < 50 bpm, uncontrolled hypertension, myocardial infarction or unstable angina within the past 6 months), hepatic insufficiency (ALT/AST > 2× upper limit of normal), renal insufficiency (eGFR < 30 mL/min/1.73m² or maintenance dialysis), neuropsychiatric dysfunction, or inability to cooperate with pain assessment.
- History of chronic pain.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Anrikefon InjectionActive ingredient: Anrikefon. Specification: 1 mL: 0.1 mg. Dosage: diluted to working solution of 10 μg/mL in 100 mL; loading dose 1.0 μg/kg; PCA bolus 2 mL per demand; lockout interval 15 min. | Drug | Anrikefon (HSK21542) Group |
| Sufentanil Citrate InjectionSpecification: 1 mL: 50 μg. Dosage: 2 μg/kg diluted to 100 mL solution; loading dose 0.1 μg/kg; PCA bolus 2 mL per demand; lockout interval 15 min. | Drug | Sufentanil Group |
Primary outcome
Sum of Pain Intensity Difference over 24 Hours (SPID₂₄)
Time frame: 0 to 24 hours after first dose
6 secondary outcomes
Number and Dose of Rescue Medication
Time frame: 0 to 24 hours after first dose
Incidence of Postoperative Nausea and Vomiting (PONV) at 24 Hours
Time frame: 0 to 24 hours after first dose
PCA Pump Demand (Total, Effective, and Delivered Dose)
Time frame: 0 to 24 hours after first dose
Time to First Rescue Medication
Time frame: 0 to 24 hours after first dose
Proportion of Subjects Requiring Rescue Medication
Time frame: 0 to 24 hours after first dose
Treatment Failure Rate Due to Inadequate Analgesia
Time frame: 0 to 24 hours after first dose
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Sep 2026.
- Individual participant dataSharing planned: No
Related trials for Postoperative Pain
RecruitingPhase 4
ESP Blocks for Posterior Spinal Fusion
Postoperative Pain
Recruiting
Effect of Cryotherapeutic and Nanotherapeutic Sodium Hypochlorite on Post-Operative Endodontic Pain.
Symptomatic Irreversible Pulpitis, Symptomatic Apical Periodontitis
RecruitingPhase 2
REctus Sheath Trial
Acute Pain, Postoperative Pain, Acute
Not yet recruiting
Effect of Pectoral Nerve Block (PECS) Using Magnesium Sulfate Added to Dexamethasone on Quality of Recovery and Chronic Post-Mastectomy Pain
Breast Cancer, Postoperative Pain
Active, not recruitingPhase 4
Effect of Dexmedetomidine on Postoperative Pain in Spinal Anesthesia for Cesarean Section at Assuit University Hospital
Cesarean Section
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
A study testing Anrikefon Injection and Sufentanil Citrate Injection in people with Postoperative Pain, run by The First People's Hospital of Lianyungang.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 9 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Sum of Pain Intensity Difference over 24 Hours (SPID₂₄) (time frame: 0 to 24 hours after first dose). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Sep 2026.